|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Harpoon Therapeutics, Inc. (HARP) |
|
|
$0.89 0.00 (0.00%) as of 4:30 Fri 9/1
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
32,670,000 |
Market
Cap: |
29.20(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.615 - $1.06 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Harpoon Therapeutics is a clinical-stage immunotherapy company. Co.'s Tri-specific T cell Activating Construct (TriTACs) product candidates include: HPN328, which is for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217, which is for the treatment of multiple myeloma; and HPN536, which is for the treatment of ovarian and pancreatic cancers and other mesothelin- expressing solid tumors. Co.'s proprietary TriTAC product candidate is HPN601, which targets the epithelial cell adhesion molecule and is being developed for the treatment of multiple solid tumor indications.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
21,397,205 |
21,397,205 |
24,484,205 |
24,494,205 |
Total Buy Value |
$492,135,715 |
$492,135,715 |
$492,135,715 |
$502,135,715 |
Total People Bought |
1 |
1 |
3 |
3 |
Total Buy Transactions |
1 |
1 |
4 |
5 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Sacks Natalie |
Chief Medical Officer |
|
2019-12-02 |
4 |
AS |
$17.98 |
$104,751 |
D/D |
(5,826) |
45,754 |
|
- |
|
Sacks Natalie |
Chief Medical Officer |
|
2019-12-02 |
4 |
OE |
$2.12 |
$12,351 |
D/D |
5,826 |
51,580 |
|
- |
|
Sacks Natalie |
Chief Medical Officer |
|
2019-11-18 |
4 |
AS |
$13.33 |
$243,964 |
D/D |
(18,252) |
45,754 |
|
- |
|
Sacks Natalie |
Chief Medical Officer |
|
2019-11-18 |
4 |
OE |
$2.12 |
$38,694 |
D/D |
18,252 |
64,006 |
|
- |
|
Sacks Natalie |
Chief Medical Officer |
|
2019-11-01 |
4 |
AS |
$13.17 |
$76,702 |
D/D |
(5,826) |
45,754 |
|
- |
|
Sacks Natalie |
Chief Medical Officer |
|
2019-11-01 |
4 |
OE |
$2.12 |
$12,351 |
D/D |
5,826 |
51,580 |
|
- |
|
Sacks Natalie |
Chief Medical Officer |
|
2019-10-15 |
4 |
AS |
$13.21 |
$154,481 |
D/D |
(11,698) |
45,754 |
|
- |
|
Sacks Natalie |
Chief Medical Officer |
|
2019-10-15 |
4 |
OE |
$2.12 |
$24,800 |
D/D |
11,698 |
57,452 |
|
- |
|
Sacks Natalie |
Chief Medical Officer |
|
2019-10-14 |
4 |
AS |
$13.27 |
$165,280 |
D/D |
(12,452) |
45,754 |
|
- |
|
Sacks Natalie |
Chief Medical Officer |
|
2019-10-14 |
4 |
OE |
$2.12 |
$26,398 |
D/D |
12,452 |
58,206 |
|
- |
|
Mcmahon Gerald Phd |
President and CEO |
|
2019-06-05 |
4 |
OE |
$0.60 |
$101,677 |
D/D |
169,462 |
172,462 |
|
- |
|
Mcmahon Gerald Phd |
President and CEO |
|
2019-05-14 |
4 |
B |
$10.16 |
$10,157 |
D/D |
1,000 |
3,000 |
2.81 |
- |
|
Mcmahon Gerald Phd |
President and CEO |
|
2019-05-08 |
4 |
B |
$10.56 |
$10,559 |
D/D |
1,000 |
2,000 |
2.81 |
- |
|
Mcmahon Gerald Phd |
President and CEO |
|
2019-05-03 |
4 |
B |
$10.53 |
$10,530 |
D/D |
1,000 |
1,000 |
2.81 |
- |
|
Hunt Ronald |
Director |
|
2019-02-12 |
4 |
B |
$14.00 |
$5,999,994 |
I/I |
428,571 |
678,566 |
2.25 |
- |
|
Hunt Ronald |
Director |
|
2019-02-12 |
4 |
A |
$0.00 |
$0 |
I/I |
2,492,834 |
464,281 |
|
- |
|
Mpm Oncology Impact Management Gp Llc |
10% Owner |
|
2019-02-12 |
4 |
B |
$14.00 |
$3,500,000 |
D/D |
250,000 |
3,898,422 |
2.45 |
- |
|
Mpm Oncology Impact Management Gp Llc |
10% Owner |
|
2019-02-12 |
4 |
S |
$14.00 |
$6,258 |
D/D |
(447) |
3,648,422 |
|
- |
|
Mpm Oncology Impact Management Gp Llc |
10% Owner |
|
2019-02-12 |
4 |
OE |
$0.05 |
$6,253 |
D/D |
127,096 |
3,648,869 |
|
- |
|
Mpm Oncology Impact Management Gp Llc |
10% Owner |
|
2019-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
3,521,773 |
3,521,773 |
|
- |
|
Chin Mark |
Director |
|
2019-02-12 |
4 |
B |
$14.00 |
$5,999,994 |
I/I |
428,571 |
2,892,119 |
2.25 |
- |
|
Chin Mark |
Director |
|
2019-02-12 |
4 |
A |
$0.00 |
$0 |
I/I |
2,463,548 |
2,463,548 |
|
- |
|
Evnin Luke |
Director |
|
2019-02-12 |
4 |
B |
$14.00 |
$3,500,000 |
I/I |
250,000 |
4,524,425 |
2.25 |
- |
|
Evnin Luke |
Director |
|
2019-02-12 |
4 |
D |
$14.00 |
$21,336 |
I/I |
(1,524) |
4,274,425 |
|
- |
|
Evnin Luke |
Director |
|
2019-02-12 |
4 |
OE |
$0.05 |
$21,260 |
I/I |
432,119 |
4,275,949 |
|
- |
|
213 Records found
|
|
Page 8 of 9 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|